Ghent-based biotech company 4Tissue has successfully raised €1.5M through equity investments and grants to further its research in bioresorbable hydrogel technology. This innovation aims to improve breast reconstruction and tissue regeneration, with plans for initial clinical trials and recruitment in regulatory affairs. Notably, Dr. Katleen Verleysen, an experienced biotech leader, has joined as chair to guide strategic growth and funding efforts for 4Tissue. The company, a spin-off from Ghent University and other institutions, focuses on pioneering solutions in regenerative medicine for breast cancer recovery.
"4Tissue is on the verge of revolutionising breast reconstruction after a breast cancer treatment and regenerative medicine, and I am excited to contribute to this transformation."
"It's not just a technical breakthrough-it's a solution that can drastically improve the lives of women recovering from breast cancer, a disease that affects millions worldwide."
Collection
[
|
...
]